FDA Approves Atogepant to Prevent Chronic Migraine in Adults

Atogepant becomes the first oral CRGP receptor antagonist approved to prevent both episodic and chronic ...

APRIL 19, 2023

FDA Clears Remote Electrical Neuromodulation Device for Use in Younger Patients

The FDA cleared a remote electrical neuromodulation device for acute treatment of migraine in children as young as ...

FEBRUARY 1, 2021

Remote Electrical Neuromodulation Is Next Chronic Migraine Therapy

A remote electrical neuromodulation device, previously approved by the FDA for the acute treatment of episodic ...

DECEMBER 8, 2020

FDA Expands Neuromodulation Device Indication to Chronic Migraine

The FDA expanded the indication of a remote electrical neuromodulation device to include patients with chronic ...

NOVEMBER 9, 2020

FDA Approves New Anti-CGRP Injection for Adult Migraine Prevention

The FDA has approved fremanezumab-vfrm injection for the prevention of migraines in adults. Fremanezumab-vfrm is an ...

SEPTEMBER 20, 2018

Readmission Rates for Pain Higher for Migraineurs

Patients with a history of migraines are at increased risk for hospital readmission due to pain within 30 days.

JULY 11, 2018

Sphenopalatine Ganglion Block a Viable Therapy for Migraine in Pregnant Patients

Pregnant patients presenting with chronic migraines should be considered for sphenopalatine ganglion block ...

MAY 21, 2018

New Monoclonal Antibody Targets Pathway to Prevent Migraine

The investigational monoclonal antibody galcanezumab has demonstrated efficacy in preventing both episodic and ...

FEBRUARY 15, 2018

Study Finds Noninvasive VNS Safe, Effective For Chronic Migraine Headache Prevention

Self-administered, noninvasive vagus nerve stimulation using the gammaCore device is a safe, tolerable and ...

OCTOBER 17, 2016

Migraine Chronicity Linked to Increased Fibromyalgia Pain Severity

The frequency and chronicity of migraine may increase sensitivity to pain in patients with fibromyalgia, according ...

OCTOBER 14, 2016